Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.


SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.

Rochlitz C, Bigler M, von Moos R, Bernhard J, Matter-Walstra K, Wicki A, Zaman K, Anchisi S, Küng M, Na KJ, Bärtschi D, Borner M, Rordorf T, Rauch D, Müller A, Ruhstaller T, Vetter M, Trojan A, Hasler-Strub U, Cathomas R, Winterhalder R; Swiss Group for Clinical Cancer Research (SAKK)..

BMC Cancer. 2016 Oct 10;16(1):780.

 

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research..

Clin Lung Cancer. 2016 Nov 23. pii: S1525-7304(16)30361-8. doi: 10.1016/j.cllc.2016.11.007. [Epub ahead of print]

 

143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial.

Gautschi O, Li Q, Matter-Walstra K, Betticher D, Frueh M, Rauch D, Pless M, Froesch P, Mach N, Ochsenbein A.

J Thorac Oncol. 2016 Apr;11(4 Suppl):S120. doi: 10.1016/S1556-0864(16)30253-2. Epub 2016 Apr

A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing.

Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; SAKK.

J Thorac Oncol. 2016 Jun 13. pii: S1556-0864(16)30507-X. doi: 10.1016/j.jtho.2016.05.032. [Epub ahead of print]

 

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jun 8. [Epub ahead of print]

 

A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.Klazien Matter-Walstra, Matthias Schwenkglenks, Peter Brauchli, Dirk Klingbiel, Konstantin J. Dedes;J Clin Oncol 34, 2016 (suppl; abstr 567)

 

Bevacizumab continuation versus treatment holidays after first-line chemotherapy with bevacizumab in patients with metastatic colorectal cancer: a health economic analysis of a randomised phase III trial (SAKK 41/06)

Klazien Matter-Walstra, Matthias Schwenkglenks, Daniel Betticher, Roger von Moos, Daniel Dietrich, Daniela Baertschi, Dieter Koeberle, DOI: http://dx.doi.org/10.1016/j.clcc.2016.03.002 Publication stage: In Press Accepted Manuscript
Published online: March 30 2016

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Konzelmann I, Mousavi M, Clough-Gorr KM, Szucs T, Schwenkglenks M, Pestalozzi BC.

Eur J Cancer Care (Engl). 2016 Feb 9. doi: 10.1111/ecc.12453. [Epub ahead of print]

 

Is the EQ-5D suitable for use in oncology? An overview of literature and recent developments.

Schwenkglenks M, Matter-Walstra K.

Expert Rev Pharmacoecon Outcomes Res. 2016 Jan 25. [Epub ahead of print]

 

Treatment specific utility-weightings are needed for cost-utility analysis in metastatic melanoma: reply from the authors.

Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M.

Br J Dermatol. 2016 Jan 20. doi: 10.1111/bjd.14279. [Epub ahead of print] No abstract available.

 

A cost-effectiveness analysis of trametinib plus dabrafenib as first-line therapy for metastatic BRAF V600-positive melanoma in the Swiss setting. Matter-Walstra K, Braun R, Kolb C, Ademi Z, Dummer R, Pestalozzi BC, Schwenkglenks M. Br J Dermatol. 2015 Sep 2. doi: 10.1111/bjd.14152. [Epub ahead of print]

 

End-of-life costs of medical care for advanced stage cancer patients. Kovacević A, Dragojević-Simić V, Rancić N, Jurisević M, Gutzwiller FS, Matter-Walstra K, Jakovljević M. Vojnosanit Pregl. 2015 Apr;72(4):334-41. Erratum in: Vojnosanit Pregl. 2015 Jul;72(7):656. Gutzwiller, Florian

 

Costs differences among monoclonal antibodies-based first-line oncology cancer protocols for breast cancer, colorectal carcinoma and non-Hodgkin's lymphoma. Jakovljevic M, Gutzwiller F, Schwenkglenks M, Milovanovic O, Rancic N, Varjacic M, Stojadinovic D, Dagovic A, Matter-Walstra K. J BUON. 2014 Oct-Dec;19(4):1111-20.

 

Resource use and costs of newly diagnosed cancer initial medical care Aleksandar Dagovic, Klazien Matter Walstra, Florian S. Gutzwiller, Natasa Djordjevic, Ana Rankovic, Gordana Djordjevic, Sanja Kocic, Dragan Vasiljevic, Predrag Canovic, Aleksandra Kovacevic, Djukic Aleksandar, Viktorija Dragojevic Simic, Mihajlo Jakovljevic, Matthias Schwenkglenks EUR. J. ONCOL.; Vol. 19, n. 3, pp. 166-184, 2014

 

Stringent adherence to a cytomegalovirus-prevention protocol is associated with reduced overall costs in the first 6 months after kidney transplantation. Matter-Walstra K, Greiner M, Cusini A, Schiesser M, Ledergerber B, Fehr T, Mueller NJ. Transpl Infect Dis. 2015 Mar 26. doi: 10.1111/tid.12379. [Epub ahead of print]

 

Cancer-Related Therapies at the End of Life in Hospitalized Cancer Patients from Four Swiss Cantons: SAKK 89/09 Matter-Walstra K.W. · Achermann R. · Rapold R. · Klingbiel D. · Bordoni A. · Dehler S. · Jundt G. · Konzelmann I. · Clough-Gorr K. · Szucs T. · Pestalozzi B.C. · Schwenkglenks M. Oncology 2015;88:18-27 (DOI:10.1159/000367629)

 

Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09)

Klazien W Matter-Walstra, Rita Achermann, Roland Rapold, Dirk Klingbiel, Andrea Bordoni, Silvia Dehler, Gernot Jundt, Isabelle Konzelmann, Kerri M Clough-Gorr, Thomas D Szucs, Matthias Schwenkglenks, Bernhard C Pestalozzi BMC Cancer 2014, 14:306 (1 May 2014)

 

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied? Matter-Walstra K, Klingbiel D, Szucs T, Pestalozzi BC, Schwenkglenks M. Pharmacoeconomics. 2014 Jun;32(6):591-9. doi: 10.1007/s40273-014-0151-0.

 

Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study.

Joerger M, Schaer-Thuer C, Koeberle D, Matter-Walstra K, Gibbons-Marsico J, Diem S, Thuerlimann B, Cerny T. Eur J Clin Pharmacol. 2014 Mar 11.

 

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M.
Value Health. 2012 Jan;15(1):65-71.


Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Ann Oncol. 2011 Mar;22(3):567-74.


Trastuzumab beyond progression: a cost-utility analysis.
Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Ann Oncol. 2010 Nov;21(11):2161-8.


Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation.

Dedes KJ, Matter-Walstra K, Schwenkglenks M, Pestalozzi BC, Fink D, Brauchli P, Szucs TD.
Eur J Cancer. 2009 May;45(8):1397-406.


Satisfaction with primary health care in patients with upper respiratory tract infection: a three-level approach.

Schoeni-Affolter F, Matter-Walstra K, Widmer M, Busato A. Forsch Komplementmed. 2007 Dec;14(6):346-52


Patient-based evaluations of primary care for cardiovascular diseases: a comparison between conventional and complementary medicine. Matter-Walstra K, Schoeni-Affolter F, Widmer M, Busato A. J Eval Clin Pract. 2008 Feb;14(1):75-82


Analysis of patient flows for orthopedic procedures using small area analysis in Switzerland. Matter-Walstra K, Widmer M, Busato A. BMC Health Serv Res. 2006 Sep 15;6:119.


Seasonal variation in orthopedic health services utilization in Switzerland: the impact of winter sport tourism. Matter-Walstra K, Widmer M, Busato A. BMC Health Serv Res. 2006 Mar 3;6:25.

 

Individuelle Entscheidungsfindung an Beispiel der Brustkrebs-Früherkennung. Erfahrungen aus Fokusgruppen in der Schweiz. Matter-Walstra KW., Hoffrage U. Managed Care, 2001

 

Atypical cells in effusions: diagnostic value of cell image analysis combined with immunocytochemistry. Matter-Walstra KW, Kraft R. Diagn Cytopathol. 1996 Nov;15(4):263-9.


Cyclosporine resistant effector cells in rabbit skin allografts. Gratwohl A, Riederer I, Walstra K, Baldomero H, Speck B.
Experientia. 1987 Aug 15;43(8):910-2.


B/T cell ratio of rabbit peripheral blood lymphocytes. Influence of separation technique on results. Walstra K, Gratwohl A, Riederer I, Speck B. J Immunol Methods. 1985 May 10;79(1):143-7.

 

Fr

21

Apr

2017

Diving Egypt

Mo

10

Apr

2017

Updated health economic analysis Palbociclib

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.

 

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

0 Kommentare

So

09

Okt

2016

Logbook Greece 2016

Logbook now online